# US 2021/0069207 A1 · Pharmaceutical solid preparation comprising benzazepines and production method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069207 A1
- Document ID: US20210069207A1
- Status: Published application
- Kind: A1
- Application number: 17/099,221
- Filed: 2020-11-16
- Published: 2021-03-11
- Earliest claimed: 2007-06-21
- Assignees: Otsuka Pharmaceutical Co., Ltd.
- Applicants: Otsuka Pharmaceutical Co., Ltd.
- Inventors: Shinsuke Nakagawa; Kai Suzuki; Tadashi Mukai
- Web page: https://patentgrep.com/patent/US20210069207A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61P 5/12: for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/12: Antihypertensives
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 μm, and a 90% cumulative particle diameter of 100 to 200 μm.

## Claims

### Claim 1

A dosing regimen for administering a benzoazepine compound to a patient in need of a vasopressin antagonist, the dosing regimen comprising:
(1) administering to the patient a first loading dose of about 45 mg of the benzoazepine compound formulated in a solid dosage form on a first day of treatment;
(2) administering to the patient a second loading dose of about 15 mg of the benzoazepine compound formulated in the solid dosage form on the first day of treatment, for a total loading dose of about 60 mg on the first day of treatment;
(3) administering to the patient a first titration dose of about 60 mg of the benzoazepine compound formulated in the solid dosage form on a second day of treatment that is after the first day of treatment;
(4) administering to the patient a second titration dose of about 30 mg of the benzoazepine compound formulated in the solid dosage form on the second day of treatment, for a total titration dose of about 90 mg on the second day of treatment;
(5) administering to the patient a first target dose of about 90 mg of the benzoazepine compound formulated in the solid dosage form on a third day of treatment that is after the second day of treatment; and
(6) administering to the patient a second target dose of about 30 mg of the benzoazepine compound formulated in the solid dosage form on the third day of treatment, for a total target dose of about 120 mg on the third day of treatment,
wherein the benzoazepine compound is selected from the group consisting of 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and a salt thereof.

### Claim 2 (depends on 1)

The dosing regimen according to claim 1, wherein the second loading dose is administered about 8 hours after the first loading dose.

### Claim 3 (depends on 1)

The dosing regimen according to claim 1, wherein the second titration dose is administered about 8 hours after the first titration dose.

### Claim 4 (depends on 1)

The dosing regimen according to claim 1, wherein the second target dose is administered about 8 hours after the first target dose.

### Claim 5 (depends on 1)

The dosing regimen according to claim 1, wherein the second day of treatment begins at least a week after the first day of treatment.

### Claim 6 (depends on 1)

The dosing regimen according to claim 1, wherein the third day of treatment begins at least a week after the second day of treatment.

### Claim 7 (depends on 1)

The dosing regimen according to claim 1, wherein the first loading dose and the second loading dose are repeated daily until the second day of treatment.

### Claim 8 (depends on 1)

The dosing regimen according to claim 1, wherein the first titration dose and the second titration dose are repeated daily until the second day of treatment.

### Claim 9 (depends on 1)

The dosing regimen according to claim 1, wherein the solid dosage form comprises:
(a) the benzoazepine compound;
(b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and
(c) low substituted hydroxypropylcellulose having an average particle diameter of 30 to 70 μm and a 90% cumulative particle diameter of 100 to 200 μm,
wherein the solid dosage form contains the (a) benzoazepine compound in an amount of 15 to 90 mg.

### Claim 10 (depends on 9)

The dosing regimen according to claim 9, wherein the solid dosage form contains a plurality of amorphous composites consisting of the (a) benzoazepine compound and the (b) hydroxypropylcellulose.

### Claim 11 (depends on 10)

The dosing regimen according to claim 10, further comprising (i) crystalline cellulose, and (ii) corn starch and/or lactose monohydrate.

### Claim 12 (depends on 9)

The dosing regimen according to claim 9, wherein the (c) low substituted hydroxypropylcellulose is cellulose containing a hydroxy propoxyl group in an amount of 10 to 13%.

### Claim 13 (depends on 9)

The dosing regimen according to claim 9, wherein the average particle diameter of the (c) low substituted hydroxypropylcellulose is 45 to 65 μm, and the 90% cumulative particle diameter of the (c) low substituted hydroxypropylcellulose is 150 to 200 μm.

### Claim 14 (depends on 9)

The dosing regimen according to claim 9, wherein the (c) low substituted hydroxypropylcellulose directly contacts at least some of the plurality of amorphous composites.

### Claim 15 (depends on 9)

The dosing regimen according to claim 9, wherein a content of the (c) low substituted hydroxypropylcellulose is 1 to 15 wt % of the solid dosage form.

### Claim 16 (depends on 9)

The dosing regimen according to claim 9, wherein the solid dosage form is a tablet.

### Claim 17 (depends on 9)

The dosing regimen according to claim 9, wherein the solid dosage form is not coated with an enteric film or a sustained-release film configured to modify a release of the benzoazepine compound in the gastrointestinal tract.

### Claim 18 (depends on 9)

The dosing regimen according to claim 9, wherein the benzoazepine compound is 0.01 to 95 wt % of the solid dosage form.

### Claim 19 (depends on 9)

The dosing regimen according to claim 9, wherein a content of (b) the hydroxypropylcellulose is 0.01 to 2 times that of the content of the (a) benzoazepine compound.

### Claim 20 (depends on 9)

The dosing regimen according to claim 9, wherein a content of the (c) low substituted hydroxypropylcellulose is 3 to 12 wt % of the solid preparation.

### Claim 21 (depends on 9)

The dosing regimen according to claim 9, further comprising crystalline cellulose, microcrystalline cellulose, corn starch, lactose monohydrate, and magnesium stearate.

### Claim 22 (depends on 9)

The dosing regimen according to claim 9, wherein the solid dosage form is obtained by a method comprising:
Step 1 of producing amorphous composites consisting of the (a) benzoazepine compound and the (b) hydroxypropylcellulose;
Step 2 of processing a mixture of (i) the amorphous composites obtained in Step 1, (ii) crystalline cellulose, and (iii) corn starch and/or lactose into granules using a granulation method;
Step 3 of mixing the granules obtained in Step 2 with the (c) low substituted hydroxypropylcellulose to obtain a mixture, wherein the (c) low substituted hydroxypropylcellulose directly contacts at least some of the amorphous composites; and
Step 4 of processing the mixture obtained in Step 3 into the solid dosage form.

### Claim 23

A dosing regimen for administering a benzoazepine compound to a patient in need of a vasopressin antagonist, the dosing regimen comprising:
(1) administering to the patient a total loading dose of about 60 mg of the benzoazepine compound on a first day of treatment;
(2) administering to the patient a total titration dose of about 90 mg of the benzoazepine compound on a second day of treatment that is after the first day of treatment; and
(3) administering to the patient a total target dose of about 120 mg of the benzoazepine compound formulated in the solid dosage form on a third day of treatment that is after the second day of treatment,
wherein the benzoazepine compound is selected from the group consisting of 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and a salt thereof.

### Claim 24

A dosing regimen for administering a benzoazepine compound to a patient in need of a vasopressin antagonist, the dosing regimen comprising:
(1) administering to the patient a plurality of initial doses of the benzoazepine compound for a total loading dose of about 60 mg of the benzoazepine compound per day;
(2) administering to the patient a plurality of titration doses of the benzoazepine compound for a total titration dose of about 90 mg of the benzoazepine compound per day; and
(3) administering to the patient a plurality of target doses of the benzoazepine compound for a total target dose of about 120 mg of the benzoazepine compound per day,
wherein the benzoazepine compound is selected from the group consisting of 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and a salt thereof.
